Drug Database
FA

famotidine (Gaster D / Gaster OD / famotidine, WOWTAB)

✓ Approved

Astellas Pharma · HRH2 · 小分子

什么是 famotidine?

famotidine 是一种小分子,由Astellas Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Gaster D, Gaster OD, famotidine, WOWTAB
公司Astellas Pharma
药物类别小分子
分子靶点HRH2
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

famotidine 作用于 1 个分子靶点:

HRH2histamine receptor H2 (H2R, HH2R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

famotidine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersGastric ulcer✓ Approved
Gastrointestinal disordersGastritis✓ Approved

相关研究文献

PubMedTherapeutic advances in gastroenterology2026-11-16

Comparative efficacy of acid-suppressive and gastroprotective agents in patients with coronary heart disease on antiplatelet therapy: A systematic review and network meta-analysis.

Zhang Yujie Y, Zhang Junyan J, Fan Xiaoli X, Ao Xiaoyan X et al.

Gastrointestinal complications remain an important clinical concern in patients with coronary heart disease (CHD) receiving antiplatelet therapy, and the comparative effectiveness of available acid-suppressive and gastroprotective strategies in this population remains uncertain. To compare the efficacy of acid-suppressive agents and gastric mucosal protectants for preventing peptic ulcer occurrence and gastrointestinal bleeding in patients with CHD receiving antiplatelet therapy. Systematic review and network meta-analysis of randomized controlled trials. PubMed, Embase, the Cochrane Library, and Ovid MEDLINE were searched from inception to May 29, 2024. Eligible trials enrolled patients receiving antiplatelet therapy, predominantly low-dose aspirin or dual antiplatelet therapy, and compared PPIs, H2RAs, P-CAB, gastric mucosal protectants, or placebo. Relative risks were synthesized using random-effects network meta-analysis, with assessment of risk of bias, inconsistency, transitivity, and small-study effects. Twenty randomized controlled trials were included. Acid-suppressive agents were generally more effective than gastroprotective agents in preventing gastrointestinal complications. For peptic ulcer occurrence, the estimated RRs versus placebo were 0.05 for vonoprazan, 0.14 for PPIs, and 0.48 for famotidine, whereas gastroprotective agents showed less consistent protective effects. For gastrointestinal bleeding, vonoprazan also showed favorable trends. However, the evidence for P-CAB was based on a limited number of trials, and its apparent advantage over PPIs should therefore be interpreted cautiously. Acid-suppressive therapies may be preferable to gastroprotective agents for preventing gastrointestinal injury in patients with CHD receiving antiplatelet therapy. P-CAB ranked highest in the current network, but this finding should be considered hypothesis-generating until confirmed by adequately powered direct comparative trials against PPIs.

PMID 43036424
阅读全文 →
PubMedIndian journal of pharmacology2026-11-02

Proton-pump inhibitor-induced severe hypomagnesemia presenting with seizure and functional hypoparathyroidism: A diagnostic challenge in long-term acid suppression therapy.

Hassan Yasir Y, Sarjanya Gampa G, Duraiswamy Jegan J, Ram Prabu P

Proton-pump inhibitors (PPIs) are popular drugs used to treat acid-related disorders. The PPIs, though effective and relatively safe, have been linked to clinically significant hypomagnesemia with long-term use, which causes potentially life-threatening complications. A 68-year-old male with an 8-year history of omeprazole 40 mg/day use presented with a generalized tonic-clonic seizure and neuromuscular irritability. Laboratory tests showed severe hypomagnesemia (0.32 mmol/L), hypocalcemia (corrected calcium 1.62 mmol/L), hypokalaemia (3.2 mmol/L), and low parathyroid hormone (12 pg/mL). 24-h urine magnesium was low (12 mg/day), suggesting external magnesium loss. Serum Vitamin D levels and renal function tests were within normal limits. Electrocardiography showed Corrected QT (QTc) interval prolongation (510 ms) with ventricular ectopy. Magnesium levels failed to normalize despite intravenous replacement until omeprazole was discontinued and replaced with famotidine. PPI-induced hypomagnesemia should be suspected in patients on long-term therapy presenting with electrolyte disturbances, seizures, or arrhythmias. Recognition is crucial, as correction is often refractory until the offending drug is withdrawn.

PMID 42969997
阅读全文 →
PubMedJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2026-10-30

Administration-related reactions following first-dose subcutaneous daratumumab to inform implementation of a 30-minute observation period.

Galvet Jennifer J, Kim Sara S SS, Caro Jessica J, Chung David J DJ

IntroductionSubcutaneous daratumumab has lower rates of administration-related reactions (ARRs) than intravenous daratumumab and shorter administration times. However, the optimal monitoring following the first dose remains uncertain and varies across institutions. This medication use evaluation assessed first-dose ARRs under a 2-h observation protocol and whether available findings support reduced 30-min observation.MethodsThis retrospective, single-center cohort study included patients who received first-dose subcutaneous daratumumab at the Zuckerberg Cancer Center between March 6, 2024, and July 31, 2025. The primary endpoint was ARR incidence. Secondary endpoints included time to onset, CTCAE version 6.0 severity, and management interventions. Premedication adherence and potential chair-time savings from reducing observation from 4 to 2 h were also evaluated. After implementation of the 30-min observation period, 26 additional patients treated from April through June 2026 were reviewed for ARRs.ResultsAmong 50 patients in the primary cohort, one experienced an ARR (2%). Grade 3 ARR occurred 150 min after administration and required intravenous methylprednisolone, diphenhydramine, famotidine, and intramuscular epinephrine. Premedication deviations included diphenhydramine 25 mg instead of 50 mg and omitted montelukast. The patient tolerated subsequent doses after receiving the complete regimen. No ARRs occurred among the 26 patients evaluated after implementation of 30-min observation.ConclusionFirst-dose subcutaneous daratumumab was associated with a low ARR incidence, with the only reaction occurring beyond 2 h. Together with published evidence and institutional experience, these findings supported implementation of 30-min observation, with no ARRs observed after implementation. Larger studies with longer follow-up are warranted to further assess abbreviated observation.

PMID 42957977
阅读全文 →
PubMedJournal of clinical densitometry : the official journal of the International Society for Clinical Densitometry2026-10-28

Association between long-term proton pump inhibitor use and bone mineral density among Jordanian adults: A retrospective study.

Massad Mu'taz M, Alqoudah Mais M, Saleh Zain Aldeen ZA, Hizzani Younis Y et al.

Osteoporosis is a common skeletal disease that is defined by low bone density and an increased risk of fracture. It is a widespread health issue with significant health consequences that has recently attracted the attention of the worldwide community. The present research was carried out to test the association between prolonged PPI therapy and bone mineral density among patients in Jordan. A retrospective observational study was performed at Al-Zarqa New Governmental and Al-Basheer Hospitals, Jordan. A total of 695 patients aged 20-60 years who underwent dual-energy X-ray absorptiometry (DEXA) were divided into 3 groups: long-term users of PPIs (≥ 12 months), famotidine users (≥ 12 months), and non-users. Bone mineral density (BMD) at the lumbar spine and femoral neck was measured using T- and Z-scores adjusted for age and sex. Of 695 participants, 180 (25.9%) were PPI users, 105 (15.1%) famotidine users, and 410 (59%) non-exposed group. The median age was 53 years, and 90.4% were female. No significant differences were found in femoral neck or lumbar spine BMD and Z-scores between groups. In the T-score group, the lumbar spine T-score differed significantly across groups (p = 0.040), driven by differences between non-exposed group and famotidine users (p = 0.034), with no significant differences involving PPI users. Our study provides the literature with unique results in support of the safety of long-term PPI use in terms of BMD. Further research is needed to explore this relationship in more robust study designs that address potential bias and confounding factors and explore it in a healthy population.

PMID 42950445
阅读全文 →
PubMedActa crystallographica. Section C, Structural chemistry2026-10-26

Copper and cobalt complexes with famotidine.

Weaver MacKenzie C MC, Oliver Allen G AG, Barstis Toni L O TLO

This research contributes to the development of Paper-Based Analytical Devices (PADs) for screening low-quality famotidine, the active pharmaceutical ingredient in Pepcid AC. While three key colorimetric chemical tests - copper(II) sulfate, cobalt(II) thiocyanate, and nickel(II) chloride - are employed on these PADs, the underlying chemistry remains poorly understood. Here we report the successful isolation and structural characterization of two new crystalline colored famotidine-metal complexes generated during PAD activation. These are a green-colored famotidine-copper(II) chloride complex, (3-{[(2-carbamimidamido-1,3-thiazol-4-yl)methyl]sulfanyl}-N-sulfamoylpropanamide)dichloridocopper(II), [CuCl2(C8H14N6O3S3)], and a blue-colored famotidine propionic acid-cobalt(II) tetrachloride complex, bis(4-{[(2-carboxyethyl)sulfanyl]methyl}-N-(diaminomethylidene)-1,3-thiazol-2-aminium) tetrachloridocobaltate(II), (C8H13N4O2S2)2[CoCl4]. Elucidating these crystal structures provides critical insights into the chemistry occurring on the activated PADs, enabling further device development and optimization.

PMID 42931791
阅读全文 →
PubMedJournal of veterinary pharmacology and therapeutics2026-10-25

Pharmacokinetics of Famotidine in Goats (Capra aegagrus hircus) After Subcutaneous Administration.

Escher-Price Olivia G OG, Smith Joe S JS, Christopher Kamryn K, Duncan Madeline M et al.

Small ruminants such as goats are susceptible to abomasal ulceration due to adverse reactions to medications, stress, and inappetence. There is limited pharmacokinetic data regarding the use of famotidine for treatment and prevention of abomasal ulceration in goats. The objective of this study is to report the pharmacokinetic parameters after a single subcutaneous administration of famotidine. Famotidine was administered at a 1.2 mg/kg dose to six healthy goats and plasma samples were collected over a 12-h period. The plasma was analyzed using reverse phase high performance liquid chromatography (HPLC) to measure famotidine concentrations. Using commercially available pharmacokinetic software, noncompartmental analysis was used to determine the pharmacokinetic parameters. The maximum plasma concentration was estimated at 735 ng/mL and the Tmax was 0.64 h. The apparent terminal half-life was 1.29 h, and the mean residence time was 1.82 h. The area under the curve was found to be 1046 h*ng/mL. Five of the 6 goats in this study had been utilized for a previous intravenous famotidine investigation, and when comparing the area under the curve to this study, the range of the estimated bioavailability after subcutaneous administration was 21.43%-135%. Future research performing a pharmacodynamic study measuring the pH of the abomasal fluid could be used to determine the efficacy of famotidine on raising pH levels. Compared to other studies with intravenous administration in goats, subcutaneous administration of famotidine may be a more useful way of maintaining concentrations over time.

PMID 42921682
阅读全文 →

注册免费账户还可查看另外 2391 篇文献

免费注册查看全部文献 →

了解更多famotidine